Project Grant R43HL184377
Award Date 8/15/26
Completion Date 8/14/27
Dollars Obligated $351K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Charlottesville, VA, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Environment & Health Group Inc. $314,321 on August 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop HeartSense.AI, a generative AI-driven mobile health solution for hypertension self-management in lower-income adults. The application describes an mHealth platform that integrates a generative AI model with home-based blood pressure monitoring, digital pill reminders, and non-physician-led telehealth to...
- The National Heart, Lung, and Blood Institute awarded Nightingale Labs Corp $1.368 million on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to commercialize non-contact cardiopulmonary monitoring technology for heart failure management. Nightingale Labs is developing a fully automated, non-contact home bed sensor platform that monitors cardiopulmonary physiology without requiring active patient participation, aimed at detecting clinical deterioration in heart...
- The National Heart, Lung, and Blood Institute awarded Prenosis, Inc. $1,218,102 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate the Heart Failure CardioScore, an artificial intelligence diagnostic tool for acute heart failure in emergency department patients. Prenosis will combine novel biomarkers and clinical data with machine learning to improve diagnostic and prognostic accuracy for acute heart failure, addressing the challenge...
- Federal Grant Award Summary Aventusoft LLC received a $500,000 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded July 15, 2025, with completion targeted for June 30, 2026. The award supports late-stage development and commercialization readiness activities for HATS-OFF (HemotTag Assessment for Short-Term Outcomes of Heart Failure), a non-invasive hemodynamic monitoring device designed to detect heart...
- The National Heart, Lung, and Blood Institute awarded Bridgesource Medical, Corp. $320,727 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a right heart catheter device that uses pressure-volume loop analysis to identify which patients with tricuspid regurgitation will benefit from percutaneous valve repair procedures. The device addresses a critical clinical gap in patient selection for tricuspid valve interventions. Approximately 1.5 million...
- The National Heart, Lung, and Blood Institute awarded Aventusoft LLC $500,000 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to advance commercialization of HEMOLINK, a skin-adhered disposable patch for non-invasive hemodynamic monitoring. HEMOLINK is a first-in-class wearable medical device featuring a synchronous quad-sensor array designed to estimate left ventricular end-diastolic pressure (LVEDP) for remote cardiac monitoring. The patch incorporates...
- The National Heart, Lung, and Blood Institute awarded Medluidics LLC $227,639 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a cardiopulmonary unit-on-a-chip for investigating right ventricular hypertrophy caused by pulmonary arterial hypertension and for developing targeted treatments. The recipient will develop a microfluidic device that models both the right ventricle and pulmonary artery separated by a collagen layer, enabling culture of...
- The National Heart, Lung, and Blood Institute (NHLBI) at the Department of Health and Human Services awarded The Leland Stanford Junior University $755,271 on August 25, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop, validate, and clinically evaluate a magnetic resonance imaging method for assessing blood flow hemodynamics in pediatric and young adult congenital heart disease patients. The project will augment 4D-flow MRI capabilities to enable direct...
- The National Heart, Lung, and Blood Institute awarded Minnesota Healthsolutions Corporation $329,537 on August 15, 2026, to develop a novel balloon angioplasty inflation device under the Cardiovascular Diseases Research program (CFDA 93.837). The recipient will design and evaluate a prototype inflation device intended to improve safety and efficacy during percutaneous balloon angioplasty by accounting for molecular composition and elasticity differences in arterial tissue. Current market devices...
- The National Heart, Lung, and Blood Institute awarded Autonomous Healthcare Inc. $305,999 on September 1, 2026, under the Small Business Innovation Research (SBIR) program to conduct a Phase I feasibility study of E-Fusion, a bedside clinical decision support system designed to assist anesthesiologists, anesthetists, and critical care nurses with vasopressor titration and blood pressure management during surgery and in the intensive care unit. The system monitors mean arterial pressure (MAP) and...